why choose us

First received: August 26, 2022

Clinical Trial: A Study of Gilteritinib, Venetoclax and Azacitidine as a Combined Treatment for People Newly Diagnosed With Acute Myeloid Leukemia

Study Status: Completed

Recruit Status: RECRUITING

Condition: Acute Myeloid Leukemia (AML)

Study Type: INTERVENTIONAL


Official Title: A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acut

Brief Summary: People with acute myeloid leukemia (AML) are usually treated with chemotherapy.Some people with AML have a changed FLT3 gene which causes leukemia cells to grow faster.Therefore, chemotherapy is less suitable to treat AML in people with the changed FLT3 gene.Gilteritinib, given with venetoclax and azacitidine, is a potential new treatment for people with AML with the changed FLT3 gene.They cannot have chemotherapy due to old age or other conditions.Before these combined 3 medicines are available as a treatment,…

Read more